EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
193
EDITION
8
PRICE
USD 4950
CODE
MCP13152
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
SELECT PLAYERS
AstraZeneca PLC; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Concordia International Corporation; Corden Pharma International GmbH; Eli Lilly and Company; F. Hoffmann-La Roche AG; Fresenius Kabi AG; Kyowa Hakko Kirin Co., Ltd.; Merck & Co., Inc.; MolMed S.p.A.; Mylan NV; Nichi-Iko Pharmaceutical Co., Ltd.; Novartis International AG; Ono Pharmaceutical Co., Ltd.; Pfizer, Inc.; Polaris Pharmaceuticals, Inc.; Sanofi S.A.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» Drug Class (Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination, Other Combinations)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Premetrexed and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Cisplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Carboplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Gemcitabine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Vinorelbine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
CHINA |
China Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
EUROPE |
Europe Current & Future Analysis for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
REST OF WORLD |
Rest of World Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 43 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com